Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.

@article{RomboutSestrienkova2012ErythrocytapheresisVP,
  title={Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.},
  author={Eva Rombout-Sestrienkova and Fred H. M. Nieman and B A B Essers and Paulus A. H. van Noord and Mirian C. H. Janssen and C Th B M van Deursen and L. P. Bos and Ferdinand Rombout and Rogier van den Braak and Peter Wilhelmus de Leeuw and Ger H. Koek},
  journal={Transfusion},
  year={2012},
  volume={52 3},
  pages={470-7}
}
BACKGROUND Standard treatment of newly diagnosed HFE hemochromatosis patients is phlebotomy. Erythrocytapheresis provides a new therapeutic modality that can remove up to three times more red blood cells per single procedure and could thus have a clinical and economic benefit. STUDY DESIGN AND METHODS To compare the number of treatment procedures between erythrocytapheresis and phlebotomy needed to reach the serum ferritin (SF) target level of 50 µg/L, a two-treatment-arms, randomized trial… CONTINUE READING